CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
75 hedge funds and large institutions have $25.6M invested in CTI BioPharma Corp. (DE) Common Stock in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 15 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
5% less funds holding
Funds holding: 79 → 75 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
67% less capital invested
Capital invested by funds: $76.7M → $25.6M (-$51M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.02M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$697K |
| 3 |
Renaissance Technologies
New York
|
+$535K |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$494K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$394K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.45M |
| 3 |
AG
Algert Global
San Francisco,
California
|
-$733K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$246K |
| 5 |
JP Morgan Chase
New York
|
-$242K |
CTIC Hedge Fund Activity: Q4 2018 in Review
75 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2018, worth a combined $25.6M — down 67% from $76.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CTIC and 11 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 22 added.
The largest buyer was Balyasny Asset Management, adding an estimated $1.02M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.05M sold.
- 75 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2018, down from 79 in Q3 2018.
- Funds reported $25.6M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2018, down 67% quarter-over-quarter.
- 11 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2018 and 15 closed out, a net change of -4 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2018 was Balyasny Asset Management, an estimated $1.02M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2018 was Fidelity Investments, an estimated $2.05M sold.
Based on aggregated 13F filings for Q4 2018.